Summary
This study will evaluate the long-term safety and tolerability of VX-659 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous or heterozygous for the F508del mutation.
Conditions
Cystic Fibrosis
Recruitment Status
Terminated
Eligibility Criteria
Inclusion Criteria:
Completed study drug treatment in a parent study; or had study drug interruption(s) in a parent study but completed study visits up to the last scheduled visit of the Treatment Period in the parent study.
Exclusion Criteria:
History of drug intolerance in a parent study that would pose an additional risk to the subject in the opinion of the investigator.
Current participation in an investigational drug trial (other than a parent study)
Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention
Intervention Type
Intervention Name
Drug
VX-659/TEZ/IVA
Drug
IVA
Phase
Phase 3
Gender
All
Min Age
12 Years
Max Age
N/A
Download Date
January 25, 2022
Principal Investigator
N/A
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
Contact
For more information and to contact the study team: